A main limitation of therapies that selectively target kinase signalling pathways is the emergence of secondary drug resistance. Cetuximab, a monoclonal antibody that binds the extracellular domain of epidermal growth factor receptor (EGFR), is effective in a subset of KRAS wild-type metastatic colorectal cancers 1 . After an initial response, secondary resistance invariably ensues, thereby limiting the clinical benefit of this drug 2 . The molecular bases of secondary resistance to cetuximab in colorectal cancer are poorly understood [3] [4] [5] [6] [7] [8] . Here we show that molecular alterations (in most instances point mutations) of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers. Expression of mutant KRAS under the control of its endogenous gene promoter was sufficient to confer cetuximab resistance, but resistant cells remained sensitive to combinatorial inhibition of EGFR and mitogen-activated protein-kinase kinase (MEK). Analysis of metastases from patients who developed resistance to cetuximab or panitumumab showed the emergence of KRAS amplification in one sample and acquisition of secondary KRAS mutations in 60% (6 out of 10) of the cases. KRAS mutant alleles were detectable in the blood of cetuximab-treated patients as early as 10 months before radiographic documentation of disease progression. In summary, the results identify KRAS mutations as frequent drivers of acquired resistance to cetuximab in colorectal cancers, indicate that the emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression and suggest early initiation of a MEK inhibitor as a rational strategy for delaying or reversing drug resistance.
Defining the molecular bases of secondary resistance to anti-EGFR therapies is crucial to monitor, prevent and/or overcome drug refractoriness. To identify potential mechanisms of cetuximab resistance, we generated cetuximab-resistant variants of two colorectal cancer (CRC) cellular models (DiFi and Lim1215 cells) that are highly sensitive to EGFR inhibition ( Supplementary Fig. 1a) . DiFi cells overexpress EGFR as a result of high level amplification of the EGFR gene locus 9 . By contrast, Lim1215 cells express 'normal' EGFR levels but are similarly sensitive to cetuximab ( Supplementary Fig. 1b, c) . Both cell lines are wild type for KRAS, BRAF and PIK3CA, paralleling the molecular features of the patients with CRC who are most likely to respond to cetuximab 10 . Continuous drug treatment using two different protocols (see Methods and Supplementary Fig. 2 ) led to the emergence of cetuximabresistant variants (termed DiFi-R and Lim1215-R; Figs 1a and 2a). To identify the molecular basis of cetuximab resistance in these cells, we performed gene copy number analysis and mutational profiling of the resistant and parental lines. Cetuximab-resistant DiFi-R cells differed from their sensitive parental counterpart by two focal molecular alterations: the EGFR gene copy number was reduced, whereas the KRAS gene was amplified (Fig. 1b, c and Supplementary Fig. 3 ). These genomic changes were accompanied by reduced EGFR and increased KRAS protein expression in the cetuximab-resistant cells (Fig. 1d) . Sequence analysis confirmed that the EGFR, KRAS, NRAS, HRAS, BRAF and PIK3CA genes were all wild type in the cetuximab-resistant clones.
Sequence analysis of the Lim1215 cetuximab-resistant variants identified acquisition of either KRAS(G13D) or KRAS(G12R) mutations (Fig. 2b) . In both DiFi-R and Lim1215-R cells, KRAS amplification and mutations, respectively, were accompanied by increased KRAS activation relative to their parental counterparts. In the presence of KRAS amplification, cetuximab could partially abrogate phosphorylation of MEK and extracellular signal-regulated kinase (ERK) but, as in KRAS mutant cells, was unable to induce growth arrest (Figs 1a, d and 2a, c).
To determine whether resistance was due to selection of pre-existing drug-resistant cells, we analysed the parental cell lines in depth for the presence of a minority population of KRAS amplified or mutant cells. In the parental DiFi cells, we identified a sub-population with high level KRAS amplification at a prevalence of approximately 1:40,000 (Supplementary Fig. 4) . Similarly, deep sequencing and BEAMing (bead, emulsion, amplification and magnetics) 11 indicated that approximately 0.2% of the parental Lim1215 cells contained the KRAS(G13D) mutation (Supplementary Table 1 ). Notably, the G12R mutation was not detectable in the earliest available passage of parental cells, even when the analysis was performed at high coverage (.50,000-fold). These results suggest that the emergence of a cetuximab-resistant population could derive from selection of a pre-existing KRAS amplified or mutant clone or as the result of 'de novo' acquisition of a KRAS mutation under the pressure of cetuximab treatment. To assess this latter possibility formally, we performed dilution cloning of the earliest available passage of Lim1215 cells to generate a homogenous, KRAS wild-type Lim1215 sub-line. As schematized in Supplementary Fig. 5 , two successive dilution cloning experiments were performed and the derivative cells (hereafter referred to as E4.1) were confirmed as KRAS wild-type by both mass spectrometry (MS)-based genotyping and 454 pyrosequencing analysis. We then cultured the E4.1 cells in increasing concentrations of cetuximab, analogous to the experiment performed with the original Lim1215 parental line. Cells were collected during intermediate passages and subjected to MS-based genotyping and/or 454 sequencing analysis ( Supplementary Fig. 5a ).
MS genotyping identified a KRAS(A146T) mutation after four passages in increasing concentrations of cetuximab (20 nM and higher; Supplementary Fig. 5b ). These cells were indeed resistant to the drug ( Supplementary Fig. 5c, d ), and showed biochemical activation of KRAS ( Supplementary Fig. 5e ). In parallel, genetic analysis of the E4.1 cells grown in medium without cetuximab found them to be KRAS wild type. In summary, these data suggest that resistance to cetuximab in Lim1215 cells may emerge not only from the selection of pre-existing KRAS mutant clones but also as a result of continuing mutagenesis.
To prove that amplification or mutations of KRAS were causally responsible for cetuximab resistance in our in vitro models, we performed two sets of forward genetic experiments. First, ectopic overexpression of wild-type KRAS in DiFi conferred resistance to cetuximab (Fig. 1e, f) . Second, adeno-associated virus (AAV)-mediated targeted homologous recombination was used to introduce (knock-in) the G13D and G12R alleles into the endogenous KRAS locus of Lim1215 cells 12 . Knock-in of the G13D or G12R mutant alleles rendered Lim1215 cells resistant to cetuximab (Fig. 2d, e) .
Patients with chemotherapy-refractory CRC, who initially respond and then become resistant to cetuximab, have no further therapeutic options. We reasoned that cetuximab resistance resulting from constitutive KRAS activation could be prevented or reversed by pharmacological inhibition of KRAS signalling. We thus co-treated the resistant clones with cetuximab and selective inhibitors of MEK kinase and phosphatidylinositol-3-OH kinase (PI(3)K)-two key downstream effectors of oncogenic KRAS. Although PI(3)K inhibitors were ineffective in the cetuximab-resistant cells, both the Lim1215-R and DiFi-R cells were sensitive to combinatorial targeting of MEK and EGFR ( Supplementary Fig. 6 ).
To determine whether KRAS mutation and/or amplification are clinically relevant mechanisms of acquired cetuximab resistance, we examined tumour biopsies from ten patients with CRC who had become refractory to either cetuximab or the anti-EGFR antibody panitumumab (Supplementary Table 2 ). We identified one individual (patient 11, Supplementary Table 3a) whose tumour at progression displayed KRAS amplification that was not present in a matched precetuximab biopsy (Supplementary Fig. 7 ). In a different patient (patient 8, Supplementary LETTER RESEARCH obtained in patients with acquired resistance to anti-EGFR therapy were wild-type KRAS by this technique (Supplementary Table 3a) . To determine whether the Sanger technology may have been underpowered to detect KRAS mutations in the biopsies obtained after cetuximab or panitumumab progression, these remaining cases were analysed using either 454 deep sequencing or BEAMing. These techniques identified the KRAS(G13D) mutation in four samples, and the simultaneous presence of G12D and G13D mutations in one case (Fig. 3b) . In the six patients for whom sufficient pre-treatment tumour samples were available for high coverage 454 sequence analysis or BEAMing, KRAS mutations were absent pre-treatment (Supplementary Table 3b ). Tumours from a further eight patients treated with cytotoxic chemotherapy but not previously exposed to anti-EGFR therapies were also analysed by 454 deep sequencing. In all eight cases (patients 13-21), 454 sequence analyses identified no evidence of KRAS mutation (Fig. 3a) . These results indicate that treatment with anti-EGFR antibodies but not cytotoxic chemotherapy is associated with the acquisition of KRAS mutations (P 5 0.0193) (Fig. 3c) . Our data support the initiation of clinical trials to define the prevalence of KRAS alterations as a mechanism of acquired resistance to anti-EGFR therapies through systematic collection of biopsies. Emergence of secondary resistance to cetuximab (disease progression) is presently established by radiological evaluation, and typically occurs within 9 to 18 months. We reasoned that the detection of KRAS mutant alleles in the plasma of patients treated with cetuximab or panitumumab may allow the early identification of individuals at risk for this mechanism of drug resistance before radiographic documentation of disease progression. We thus performed BEAMing analysis of serial plasma samples from patients treated with cetuximab (Supplementary Table 4a , b). This analysis confirmed that the same KRAS variants that were ultimately identified in the post-treatment (disease progression) biopsies were detectable in plasma as early as 10 months before the documentation of disease progression by radiological assessment (Fig. 4) .
Drugs that target activated kinase pathways have profound but often temporary anti-tumour effects in subsets of patients with advanced solid tumours. In patients with advanced CRC, antibodies that bind to the extracellular domain of EGFR induce tumour regressions in 10-15% of patients when used alone, and enhance the effects of cytotoxic chemotherapies when used in combination 13, 14 . Although several previous studies have identified somatic mutations in the KRAS gene as a biomarker of intrinsic resistance to EGFR-targeted agents in patients with CRC 2, 15 , the molecular basis for acquired resistance has remained obscure. We now report, for the first time, that a substantial fraction of CRC patients who exhibit an initial response to anti-EGFR therapies have, at the time of disease progression, tumours with focal amplification or somatic mutations in KRAS that were not detectable before the initiation of therapy. Our data indicate that drug resistance resulting from alterations in KRAS can be attributed not only to the selection of pre-existent KRAS mutant and amplified clones, but also to new mutations that arise as the result of continuing mutagenesis. The percentage of KRAS mutant alleles detected in the resistant tumours ranged from 0.4 to 17% (Fig. 3) . At least three (not mutually exclusive) possibilities could account for this low allele frequency. First, despite our efforts to maximize tumour content by macrodissecting each sample, the individual tumour biopsies consisted of variable proportions of tumour and intermixed wild-type KRAS stromal cells. Second, only a fraction of the tumour cells in the disease progression samples may have contained the 'resistance' mutation. The latter model has been observed in patients with lung cancer with secondary resistance to the EGFR inhibitor erlotinib, in which only a fraction of the tumour cells collected at the time of radiographic disease progression contain 
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the EGFR(T790M) 'resistant' allele [16] [17] [18] . Analogously, a recent study indicates that a subset of colorectal cancers found to be wild-type KRAS by conventional Sanger sequencing, but KRAS mutant by more sensitive techniques, do not respond to anti-EGFR treatment 19 . These data suggest that clinical drug resistance may result from the acquisition of a drug-resistant allele in a sub-population of tumour cells. Finally, it is plausible that independent cell populations containing different resistance mechanisms evolve in parallel within the same metastatic lesion. Nevertheless, our functional analyses in cell models show that KRAS mutations are causally responsible for acquired resistance to cetuximab.
Furthermore, we find that the KRAS mutant alleles found in the tumours of patients collected after radiographic disease progression can be detected in plasma using highly sensitive DNA analysis methods. As such tumours may be sensitive to combined treatment with a MEK inhibitor, our results suggest that blood-based noninvasive monitoring of patients undergoing treatment with anti-EGFR therapies for the emergence of KRAS mutant clones could allow for the early initiation of combination therapies that may delay or prevent disease progression.
METHODS SUMMARY
DiFi and Lim1215 cells were exposed to different doses of cetuximab as described in Supplementary Fig. 2 to obtain the resistant variants. Cell viability was assessed by ATP content. Cells were seeded in 100 ml medium in 96-well plastic culture plates. The experimental procedures for knock-in of cancer mutations, the vectors, AAV production, cell infection and screening for recombinants have been described elsewhere 12 . Tumour specimens were obtained through protocols approved by the Institutional Review Board of Memorial Sloan-Kettering Cancer Center (protocol 10-029) and Ospedale Niguarda Ca' Granda (protocols 1014/09 and 194/2010). Details about the clinical characteristics of patients are provided in Supplementary Table 2 . Identification of cancer mutations in the KRAS, HRAS, NRAS, BRAF, PIK3CA and EGFR genes was performed with different sequencing platforms (Sanger, 454 pyrosequencing and mass spectrometry), as described in detail in the Methods. For immunoblot analysis, total cellular proteins were extracted by solubilizing the cells in boiling SDS buffer. Western blot detection was done by enhanced chemiluminescence. The analysis of KRAS activation was performed by immunoprecipitation assay with a glutathione S-transferase (GST) fusion protein containing the Ras-binding domain (RBD) of RAF1 (GST-RAF1-RBD). Real-time PCR was performed using an ABI PRISM 7900HT apparatus (Applied Biosytems). KRAS protein expression was evaluated by immunohistochemistry performed on 3-mm-thick tissue sections using a specific KRAS (F234) antibody (SC-30, mouse monoclonal IgG 2a Santa Cruz Biotechnology). BEAMing was performed essentially as described previously 10 , with deviations from the original protocol outlined in Methods. FISH experiments were conducted with the histology FISH accessory kit (Dako). Data are presented as mean 6 s.d. and n 5 3. Statistical significance was determined by a paired Student's t-test or unpaired Mann-Whitney test. P , 0.05 was considered statistically significant. Statistical analysis. Data are presented as the mean 6 s.d. and n 5 3. Statistical significance was determined by a paired Student's t-test or two-tailed unpaired Mann-Whitney test (Fig. 3c) . P , 0.05 was considered statistically significant.
